Cells, Volume 8, Issue 1 (January 2019) – 78 articles
Cover Story (view full-size image): A schematic illustration of the EXPAND trial outcomes is shown in the upper part. Both aspects of multiple sclerosis—inflammation and neurodegeneration—were ameliorated by the spingosine 1 phosphate receptor modulator siponimod/BAF312 (Novartis). The lower part of the figures demonstrates the proposed mode of action of siponimod. Note that following this concept, the anti-inflammatory activity of siponimod is at least in part due to direct interactions with brain cells. Since several studies have demonstrated that degenerative events within the central nervous system can trigger the recruitment of peripheral immune cells into the brain, siponimod-mediated protection of brain damage secondarily results in less severe inflammation. View this paper.
- Issues are regarded as officially published after their release is announced to the table of contents alert mailing list.
- You may sign up for e-mail alerts to receive table of contents of newly released issues.
- PDF is the official format for papers published in both, html and pdf forms. To view the papers in pdf format, click on the "PDF Full-text" link, and use the free Adobe Reader to open them.